Items tagged with Treatment
Researchers announce new discovery to evaluate TB treatments (post)
Researchers discover an important new way to compare the effectiveness of tuberculosis treatments that will have crucial implications for combatting the global tuberculosis epidemic. This research is led by scientists at the University of Colorado Anschutz Medical Campus, Colorado State University and University of California San Francisco.
Bedaquiline plus delamanid may be viable option for multidrug-resistant TB (post)
Patients with multidrug-resistant or rifampicin-resistant tuberculosis (TB) and a normal baseline QTc interval may benefit from bedaquiline plus delamanid combination therapy, according to the findings of a study published in The Lancet Infectious Diseases.
Low-dose amikacin as alternative treatment for multidrug-resistant TB (post)
Low-dose amikacin with appropriate dose adjustment based on adequate monitoring demonstrated limited toxicity with positive outcomes as a treatment option for multidrug-resistant tuberculosis (MDR-TB), according to the findings of a retrospective cohort study published in BMC Infectious Diseases.
WHO announces updates on the treatment of drug-susceptible TB (post)
14 June 2021, Geneva | A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme announced updates to the current treatment regimen for people with TB. A review of evidence by WHO has shown similar performance of a shorter treatment regimen compared to the current standard regimen, both in terms of efficacy and safety. The 4-month regimen, which is shorter, effective and all-oral, would be a preference for many patients and also national TB programmes, allowing faster cure and easing the burden on both patients and the healthcare system. Shortened treatment has the potential to improve adherence and reduce patient and health system costs.
Praedicare Inc. receives grant to evaluate potential new drug regimens for TB (post)
DALLAS, June 17, 2021 -- Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicare’s in vitro hollow fiber model of tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.
Common antibiotic found useful in accelerating recovery in TB patients (post)
Researchers have discovered that the use of a common antibiotic, doxycycline, in combination with TB drug treatment, reduces the size of lung cavities and accelerates markers of lung recovery. This was done in a trial with 30 pulmonary TB patients.
Webinar: Challenging patent barriers in accessing new TB treatments - recording now available online (post)
On 30 June 2021, the Third World Network and People's Health Movement conducted a webinar to discuss challenges in accessing affordable new TB treatments, new treatments in the pipeline, the trends in patenting and implications for access.
WHO: New invitation for expression of interest to manufacturers of antituberculosis medicines (post)
To support national and global efforts to increase access to and the affordability of TB care and treatment, the World Health Organization (WHO), together with UNICEF, UNAIDS and Unitaid, invites manufacturers of selected pharmaceutical products to submit expressions of interest for product evaluation to the WHO Prequalification Unit.
ZeNix trial results show effectiveness of regimen against highly drug-resistant TB (post)
The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
Sex differences in mortality after TB treatment (post)
All-cause mortality was found to be higher in men vs women after treatment for tuberculosis (TB), according to results from a retrospective cohort study and a meta-analysis published in Clinical Infectious Diseases.
Page 58 of 108 · Total posts: 0
←First 57 58 59 Last→